Thus, establishing functionality and inhibitor sensitivities for all EGFR missense variants, both for those already observed in patients as well as mutants that have not yet been reported but might have functional impact, could potentially allow patients with non-canonical EGFR-mutant cancers to benefit from existing approved EGFR-targeted drugs. This evidence concerns the gene EGFR and cancer.